Analyzing Collegium Pharmaceutical (NASDAQ:COLL) & Alpha Cognition (NASDAQ:ACOG)

Alpha Cognition (NASDAQ:ACOG – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Alpha Cognition and Collegium Pharmaceutical”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alpha Cognition $10.22 million 17.69 -$20.67 million ($1.10) -7.55
Collegium Pharmaceutical $815.19 million 0.97 $62.87 million $1.00 25.32

Collegium Pharmaceutical has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alpha Cognition and Collegium Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alpha Cognition -147.26% -50.90% -41.23%
Collegium Pharmaceutical 4.68% 85.14% 13.80%

Risk and Volatility

Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Alpha Cognition and Collegium Pharmaceutical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Cognition 0 0 5 0 3.00
Collegium Pharmaceutical 0 2 7 1 2.90

Alpha Cognition currently has a consensus price target of $18.20, suggesting a potential upside of 119.28%. Collegium Pharmaceutical has a consensus price target of $44.88, suggesting a potential upside of 77.23%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, equities analysts plainly believe Alpha Cognition is more favorable than Collegium Pharmaceutical.

Summary

Collegium Pharmaceutical beats Alpha Cognition on 9 of the 13 factors compared between the two stocks.

About Alpha Cognition

(Get Free Report)

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.